• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    Eleven new members join DF/HCC

    Eleven individuals have recently joined DF/HCC

    DF/HCC Researchers Reinvent Anti-tumor IL-2 Therapy for GVHD

    Graft-versus-host disease (GVHD) often occurs after an allogeneic hematopoietic stem cell transplant (HSCT) from a healthy donor is given to treat hematological cancers

    DNA Resource Core

    The DNA Resource Core provides access to specialized resources such as rapid and user friendly high-throughput DNA sequencing, a cDNA/RNAi clone repository, and distribution services and informatics support

    Tumor Imaging Metrics Core

    Under the direction of Annick Van den Abbeele, MD (DFCI) and Gordon Harris, PhD (MGH), the Tumor Imaging Metrics Core (TIMC) provides objective assessment of imaging response to treatments being evaluated through approved cancer clinical trials across the five DF/HCC hospitals (BIDMC, BWH, CHB, DFCI, MGH) using independent tumor measurements of radiological scans (CT, MR and PET).  With convenient locations at BWH, DFCI and MGH, the TIMC produces high-quality data with fast turnaround time

    A first of its kind scaffold vaccine

    For cancer immunologists who have long envisioned a vaccine that would train the immune system to rid itself of cancer, Provenge, the first therapeutic cancer vaccine to receive FDA approval in 2011, is a milestone worth celebrating

    Overcoming cancer’s immune suppression

    In 2010 and 2011, the FDA approved two novel cancer immunotherapies, the first therapeutic cancer vaccine called Provenge (sipuleucel-T), and a monoclonal antibody called Yervoy (ipilimumab) for metastatic melanoma

    Request for Applications: Harvard Catalyst – Dana-Farber/Harvard Cancer Center Pilot Grant Program
Displaying results 64 to 70 out of 229